Department of Obstetrics and Gynecology, University Hospital Münster, Albert-Schweitzer Campus 1, Gebäude A1, 48149 Münster, Germany.
Department of Obstetrics and Gynecology, University Hospital Münster, Münster, Germany.
J Perinat Med. 2019 Oct 25;47(8):811-816. doi: 10.1515/jpm-2019-0291.
Background The aim of this study was to compare transabdominal and transcervical chorionic villus sampling (CVS) as well as amniocentesis (AC) with respect to their rates of premature delivery and fetal growth restriction. Methods We retrospectively evaluated the mentioned procedures of invasive prenatal testing performed in a single center between 2001 and 2016. Seven hundred and ninety-nine cases of AC and 719 cases of CVS were included, of which 400 were performed transvaginally. Only singleton pregnancies with a normal karyotype and delivery after 24 + 0 weeks of gestation were included. Fetal growth restriction was defined as birth weight below the 10th percentile. Premature delivery was defined as delivery before 37 + 0 weeks of gestation. Data were compared to a control group without an invasive procedure. Results The frequency of premature delivery was 8.5% after transabdominal CVS, 6.3% after transcervical CVS and 10.5% after AC as compared to 10.8% in the control group. The frequency of fetal growth restriction was 8.2% after transabdominal CVS 6.8% after transcervical CVS and 8.4% after AC as compared to 9.7% in the control group. Conclusion Our study supports that the three different methods of invasive prenatal testing do not lead to a higher risk of either premature delivery or fetal growth restriction when compared to controls. We found no difference in risk profile among the three techniques.
背景 本研究旨在比较经腹和经宫颈绒毛膜取样(CVS)以及羊膜穿刺术(AC)在早产率和胎儿生长受限方面的差异。
方法 我们回顾性评估了 2001 年至 2016 年在单中心进行的上述侵袭性产前检测。纳入了 799 例 AC 和 719 例 CVS,其中 400 例经阴道进行。仅纳入正常核型、孕 24+0 周后分娩的单胎妊娠。胎儿生长受限定义为出生体重低于第 10 百分位。早产定义为妊娠 37+0 周前分娩。将数据与未行侵袭性操作的对照组进行比较。
结果 与对照组(10.8%)相比,经腹 CVS 后早产率为 8.5%,经宫颈 CVS 后早产率为 6.3%,AC 后早产率为 10.5%。经腹 CVS 后胎儿生长受限发生率为 8.2%,经宫颈 CVS 后为 6.8%,AC 后为 8.4%,对照组为 9.7%。
结论 本研究支持与对照组相比,三种不同的侵袭性产前检测方法并不会增加早产或胎儿生长受限的风险。我们未发现三种技术的风险特征存在差异。